AU2012207393A1 - Quinazolinone inhibitors of dynein - Google Patents

Quinazolinone inhibitors of dynein Download PDF

Info

Publication number
AU2012207393A1
AU2012207393A1 AU2012207393A AU2012207393A AU2012207393A1 AU 2012207393 A1 AU2012207393 A1 AU 2012207393A1 AU 2012207393 A AU2012207393 A AU 2012207393A AU 2012207393 A AU2012207393 A AU 2012207393A AU 2012207393 A1 AU2012207393 A1 AU 2012207393A1
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
chosen
halogen
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012207393A
Other languages
English (en)
Inventor
James K. Chen
Ari J. FIRESTONE
Tarun M. Kapoor
Joshua S. WEINGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2012207393A1 publication Critical patent/AU2012207393A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012207393A 2011-01-20 2012-01-18 Quinazolinone inhibitors of dynein Abandoned AU2012207393A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434545P 2011-01-20 2011-01-20
US61/434,545 2011-01-20
PCT/US2012/021639 WO2012099916A1 (en) 2011-01-20 2012-01-18 Quinazolinone inhibitors of dynein

Publications (1)

Publication Number Publication Date
AU2012207393A1 true AU2012207393A1 (en) 2013-08-08

Family

ID=45774309

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012207393A Abandoned AU2012207393A1 (en) 2011-01-20 2012-01-18 Quinazolinone inhibitors of dynein

Country Status (7)

Country Link
US (1) US9145376B2 (OSRAM)
EP (1) EP2665712A1 (OSRAM)
JP (1) JP2014506565A (OSRAM)
AU (1) AU2012207393A1 (OSRAM)
CA (1) CA2824925A1 (OSRAM)
IL (1) IL227490A0 (OSRAM)
WO (1) WO2012099916A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015221969A1 (de) * 2015-11-09 2017-05-11 Technische Universität Dresden Verfahren zur automatisierten Detektion einer Aktivität von Wirkstoffen in einer Lösung
KR102672900B1 (ko) * 2016-09-01 2024-06-10 (주)아모레퍼시픽 2,4-디클로로-a-(3,4-디하이드로-4-옥소-2(1H)-퀴나졸리닐리덴)-β-옥소-벤젠프로판니트릴을 포함하는 멜라닌 증진용 조성물
EP3624805A4 (en) * 2017-05-18 2020-11-18 Tarun M. Kapoor PYRAZOLOCHINAZOLINONE ANTITUMOR AGENTS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0995485A (ja) * 1995-03-16 1997-04-08 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
US20050080138A1 (en) 1999-09-16 2005-04-14 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2003074497A1 (en) * 2002-03-01 2003-09-12 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
US20060052345A1 (en) * 2002-11-04 2006-03-09 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
EP2177188B1 (en) 2003-02-12 2015-11-04 The Procter and Gamble Company Absorbent Core For An Absorbent Article
WO2007124171A2 (en) * 2006-04-20 2007-11-01 Massachusetts Institute Of Technology Compositions and methods for treating trinucleotide repeat disorders
WO2008015265A1 (de) * 2006-08-04 2008-02-07 Æterna Zentaris Gmbh Anthracen-derivate und deren verwendung zur behandlung gutartiger und bösartiger tumorerkrankungen
US8686102B2 (en) 2007-11-02 2014-04-01 Momentive Performance Materials Inc. Textiles treated with copolymers of epoxy compounds and amino silanes having enhanced wet-strength
US20090118421A1 (en) 2007-11-02 2009-05-07 Momentive Performance Materials Inc. Copolymer of epoxy compounds and amino silanes
WO2009102864A1 (en) * 2008-02-12 2009-08-20 Stanford University Hedgehog pathway antagonists and methods of use
CN106336400A (zh) * 2008-12-08 2017-01-18 萌蒂制药国际有限公司 酪氨酸激酶蛋白受体拮抗剂

Also Published As

Publication number Publication date
US9145376B2 (en) 2015-09-29
WO2012099916A1 (en) 2012-07-26
EP2665712A1 (en) 2013-11-27
US20130296349A1 (en) 2013-11-07
JP2014506565A (ja) 2014-03-17
CA2824925A1 (en) 2012-07-26
IL227490A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
US10398679B2 (en) Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors
CN110650961B (zh) Parp抑制剂、其药物组合物、制备方法和应用
RU2681209C2 (ru) Модуляторы серин-треонинпротеинкиназ и parp
JP6912039B2 (ja) 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用
KR20080074161A (ko) ＥＰＨＢ 및 ＶＥＧＦＲ２ 키나아제 억제제로서의피라졸로[１,５-ａ]피리딘-３-카르복실산
JP2022504541A (ja) 低分子ｍｄｍ２タンパク質デグレーダー
JP2013542968A (ja) ＭＤＭ２／４とｐ５３との相互作用の阻害剤の結晶形
KR20090119768A (ko) 흑색종 치료법
TW201625620A (zh) 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
KR20090116732A (ko) Ｃｃｒ９ 활성의 억제제로서의 1-벤젠술포닐-1ｈ-인돌 유도체
JP2010536876A (ja) Ｈｄａｃインヒビター
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
CN104755084B (zh) 抑制缺氧诱导型转录因子复合体的活性的组合物和方法及其治疗肿瘤的用途
US9145376B2 (en) Quinazolinone inhibitors of dynein
KR20080069265A (ko) Ｃｃｒ9 활성의 억제제
EP3624805A1 (en) Pyrazoloquinazolinone antitumor agents
CN111432820A (zh) 异染色质基因阻抑抑制剂
KR20080076966A (ko) Ｃｃｒ9 활성의 억제제
US9611276B2 (en) Imidazo bicyclic iminium compounds as antitumor agents
JPWO2017183723A1 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
US20240391880A1 (en) KCa3.1 INHIBITORS FOR PODOCYTE PROTECTION
JP5424187B2 (ja) アシルアミノフェニル基を有する抗がん剤
KR20080070077A (ko) Ｃｃｒ9 활성의 억제제
CN111108083A (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
JP2008525356A (ja) 抗腫瘍活性を有するインドール誘導体

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application